SHR-3167

SHR-3167 is an investigational long-acting basal insulin analog from Jiangsu Hengrui, China's largest specialty pharma in oncology and metabolic disease. The molecule is in Phase 2 for Type 2 diabetes, with the lead head-to-head trial against insulin glargine (n=275) recently completed [1]. Hengrui has not publicly disclosed the molecular structure (no acylation chemistry, half-life, or formulation details released), and Hengrui's pipeline also lists a separate long-acting insulin analog candidate (INS068) [9], so the relationship between programs is unclear. The trial design (treat-to-target vs glargine in insulin-naive T2D, HbA1c at 20 weeks as primary endpoint) tells the basic story: this is being developed as a basal insulin replacement. A second Phase 2 (n=102, active not recruiting) compares fixed-dose vs individualized titration strategies, with hypoglycemia rates as the primary endpoint [2]. Three Phase 1 studies are running in parallel covering pharmacodynamics, bioavailability, and PK/PD in diabetics [3][4][5]. There is no FDA designation, no US or EU registration trial on file, and no licensing partner announced. This reads as a China-first program. SHR-3167 will almost certainly lower glucose. The commercial question is whether anything about its profile justifies competing in a market that is already commoditizing under biosimilar pressure, is being structurally eroded by GLP-1/GIP agonists (semaglutide, tirzepatide), and now has a US-approved once-weekly competitor (insulin icodec / Awiqli, FDA-approved March 26, 2026) [6].

Novel compound, never approved anywhere. Phase 2 in T2D. The lead head-to-head against insulin glargine (NCT06688123) wrapped enrollment and completed in 2026, with results not yet published [1]. The companion Phase 2 dosing-strategy trial (NCT07472725) is active not recruiting [2], meaning data should follow within roughly 12 months. Three Phase 1 trials are ongoing in PK, PD, and bioavailability work [3][4][5], which is unusual: most programs run Phase 1 before Phase 2, not alongside. The interpretation is that Hengrui is building out a fuller PK/PD package to support either a different formulation (a fixed-dose titration pen, possibly) or a different dosing interval. NCT identifiers in the 07xxxxxx range for citations [2][3][4][5] should be re-verified directly against ClinicalTrials.gov before any external publication; the lead trial NCT06688123 is the most reliably anchored. No FDA breakthrough, fast track, orphan, or RMAT designations. Insulin does not qualify for orphan status, and breakthrough requires clinical evidence of substantial improvement over existing therapy, which SHR-3167 has not shown publicly. Expected readout for the lead Phase 2 is late 2026 to early 2027 based on trial completion timing. Hengrui has not signaled a global registration path. Any US or EU development would require a separate Phase 3 program, which has not been disclosed.

Basal insulin mimics the slow trickle of insulin the pancreas releases between meals and overnight to keep blood sugar stable. In Type 2 diabetes, cells stop responding properly to insulin, so glucose stays high in the blood. Basal insulin tops up the system to bring fasting glucose down. The mechanism is the most validated in medicine: insulin has been used to treat diabetes since 1922, and modern long-acting analogs (glargine, degludec, detemir) have been on market for over two decades with hundreds of millions of patient-years of exposure. The mechanism works. The competitive question is what differentiates SHR-3167 from glargine. Long-acting analogs compete on duration of action (steadier glucose, less hypoglycemia), peak-to-trough ratio (flatter is better), and increasingly, dosing frequency. The current frontier is once-weekly basal insulin: Novo Nordisk's icodec is now approved in the EU, Canada, China, and the US, after the FDA approved Awiqli on March 26, 2026 for adults with Type 2 diabetes following the ONWARDS Phase 3 program [6]. Eli Lilly's efsitora alfa is in Phase 3 [7]. A US-approved once-weekly competitor materially raises the bar: any once-daily entrant now competes against an approved once-weekly product on injection frequency, and any once-weekly entrant from Hengrui would arrive second to a globally-marketed first-mover.

NCT06688123, the primary Phase 2 readout, randomized 275 insulin-naive T2D patients to SHR-3167 or insulin glargine over 20 weeks with HbA1c change as the primary endpoint [1]. This is the textbook treat-to-target design for basal insulin: titrate the dose upward until each patient's fasting glucose hits a preset target (typically 70 to 100 mg/dL), then measure how much HbA1c reduction each arm achieves. The statistical bar is non-inferiority: the trial is designed to show SHR-3167 is not meaningfully worse than glargine on HbA1c reduction, not that it is better. Non-inferiority is the standard regulatory bar for me-too basal insulins because the active comparator already works well. Sample size is reasonable for Phase 2 but small for any non-inferiority claim that would carry to a label. The companion trial NCT07472725 (n=102) tests whether a fixed-dose titration schedule causes more or fewer hypoglycemic events than individualized titration [2], with hypoglycemia rates as the primary endpoint. This is a safety signal study, not an efficacy study, and the small size limits its statistical power. The Phase 1 program (NCT07588906, NCT07489482, NCT07032688) is running glucose-clamp PD studies and bioavailability comparisons against glargine [3][4][5]. A glucose-clamp study is a controlled test in which researchers continuously infuse glucose into a subject and adjust the infusion rate to keep blood sugar steady; the rate of glucose infusion required (GIR) is a direct readout of how much insulin activity is present at each time point. The GIR-AUC endpoint (area under the GIR curve over time) in NCT07588906 will reveal duration and total magnitude of action, which is the single most important pharmacological data point for positioning this molecule against weekly competitors. Trial design is competent but conventional. There is no head-to-head against degludec or icodec, which limits how strong any future differentiation claim can be.

Our model estimates a 12% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 35%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by its light or open-label blinding and larger-than-typical enrollment for this phase; it is held back by the sponsor's thin or weak approval record and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is low. Basal insulin analogs lower HbA1c. The question is whether SHR-3167 matches or beats glargine, and whether it does so with less nocturnal hypoglycemia. Both are achievable bars based on precedent: degludec beat glargine on nocturnal hypoglycemia in the SWITCH trials. Safety risk centers on hypoglycemia, the on-target toxicity that has dogged the entire insulin class. Severe hypoglycemia rates in T2D were the specific issue that initially earned insulin icodec a Complete Response Letter from FDA in 2024; Novo Nordisk subsequently addressed the regulatory concerns and Awiqli was approved on March 26, 2026 for adults with T2D [6]. The icodec experience is now a precedent for both the risk surface (long half-life flat-PD insulins inherit hypoglycemia exposure) and the path to approval (it is clearable). If SHR-3167 has a long half-life and flat PD profile, it inherits the same risk surface but also the same demonstrated regulatory path. Weight gain is the second on-target signal to watch. Execution risk: Hengrui's track record in global clinical development is limited compared to Sanofi or Novo. Trial conduct in China is unlikely to be an issue; bridging studies acceptable to FDA would be. Commercial risk is the dominant failure mode and has two layers. First, glargine is available as biosimilars (Semglee, Rezvoglar) at steep discounts, US Medicare negotiated insulin caps at $35 per month, and Awiqli now competes on injection frequency. Even successful approval delivers into a price-compressed market where SHR-3167 needs a real differentiator. Second and larger: GLP-1 and dual GLP-1/GIP agonists (semaglutide, tirzepatide) are restructuring the T2D treatment cascade. They lower HbA1c, drive weight loss, and reduce or delay the need for basal insulin initiation. As GLP-1/GIP penetration in T2D rises in both the US and China, the insulin-naive addressable population shrinks, and the insulin-requiring population skews toward later-line patients who are harder to treat. SHR-3167's addressable market is a moving target that is structurally contracting in the West and contested in China, where Hengrui itself out-licensed a GLP-1/GIP portfolio (HRS-7535 oral GLP-1, HRS9531 dual agonist) to Hercules in a $400M deal [10] - meaning Hengrui is simultaneously developing the disease-modifying class that erodes its own basal insulin opportunity.

Worth watching for China-specific reasons. Hengrui already has an established diabetes franchise in China: Retagliptin (DPP-4) is a self-developed inhibitor, the company has a Phase 3 SGLT-2 program, INS068 is a previously-disclosed long-acting insulin analog candidate, and Hengrui has been actively developing both injectable and oral GLP-1 and dual GLP-1/GIP assets [9][10]. Whether Hengrui currently sells branded insulin in China at commercial scale is not clearly disclosed in English-language filings; the safer claim is diabetes-class infrastructure rather than insulin-specific commercial muscle. The China T2D market is the largest in the world by patient count, with approximately 140 million Chinese adults living with diabetes (T2D making up the great majority) and a market valued near $5B in 2025 [11]. Even a small share of the insulin-using subset is commercially material at home. SHR-3167 does not need to beat icodec or efsitora to be relevant in China; it needs to beat foreign-branded glargine on price and local availability, which it almost certainly will. For Western markets, this is noise until Hengrui announces a global development partnership or a clearly differentiated profile. The framing 'once-weekly profile changes the story entirely' is now less dramatic: once-weekly is no longer empty space because Awiqli is US-approved. A once-weekly Hengrui asset would be a follow-on to an established first-mover, not a category creator. The single most important data point coming: duration of action from NCT07588906's glucose-clamp study [3]. If the GIR-AUC profile (total insulin activity over time, measured as area under the glucose infusion rate curve in a clamp study) stays flat past 36 hours, SHR-3167 is in once-weekly territory. If it looks like glargine, it is a me-too with a domestic moat. Hengrui's own GLP-1/GIP investments suggest the company knows where the long-term value is moving, which makes SHR-3167's strategic priority within the diabetes portfolio worth questioning. Next check-in: Q4 2026 to Q1 2027 for the NCT06688123 Phase 2 readout. The deeper signal to track is whether Hengrui out-licenses SHR-3167 to a Western partner. Silence on partnership a year from now would confirm this is a China asset, not a global one. This is not investment advice.